Charles River Laboratories International, Inc. has entered a definitive agreement to acquire HemaCare Corp. for approximately $380 million in cash. HemaCare is a producer of human-derived cellular products for the cell therapy market. The company supplies critical biomaterials, including a wide range of human primary cell types, as well as cell processing services to support the discovery, development, and manufacture of cell therapies, including allogeneic (donor-derived cells) and autologou...